Evidence map›Paper›PMID 41898318›Full record

ReviewBiomedicines2026

BRAF Mutations in Myeloid Neoplasms: Prevalence, Co-Mutation Landscape, and Clinical Outcomes-A Comprehensive Review.

Shehab F Mohamed, Ali Mohamed, Mohamed Fawzi Mudarres, Azza E A Abdalla, Abdulrahman F Al-Mashdali, Mohammed Abdulgayoom, Rowan Mesilhy, Tareq Abuasab, Honar Cherif, Gautam Borthakur

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shehab F MohamedDepartment of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha 3050, Qatar.
Ali MohamedDepartment of Internal Medicine, Rochester General Hospital, Rochester, NY 14621, USA.ORCID 0000-0003-2698-2842
Mohamed Fawzi MudarresDepartment of Internal Medicine, Mercy Hospital, Saint Louis, MO 63141, USA.ORCID 0000-0002-4712-0590
Azza E A AbdallaDepartment of Internal Medicine, Rochester General Hospital, Rochester, NY 14621, USA.
Abdulrahman F Al-MashdaliDepartment of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha 3050, Qatar.
Mohammed AbdulgayoomDepartment of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha 3050, Qatar.ORCID 0000-0003-0622-8455
Rowan MesilhyDepartment of Internal Medicine, Hamad Medical Corporation, Doha 3050, Qatar.ORCID 0000-0001-8672-930X
Tareq AbuasabDepartment of Internal Medicine, Section of Hematology, Baylor College of Medicine, Houston, TX 77030, USA.ORCID 0009-0008-9205-6867
Honar CherifDepartment of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha 3050, Qatar.
Gautam BorthakurDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

acute myeloid leukemiaBRAFchronic myelomonocytic leukemiaMAPK pathwaymolecular geneticsmyeloid neoplasmstargeted therapytherapy-related AML

Identifiers

PMID41898318
PMCPMC13024105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.